Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | HPGD | P15428 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
| ▸ | RAF1 | P04049 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.37 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.37 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4847452 | 1.00 | ALDH1A1 (0.41) | ALDH1A1HPGDMAPTTP53KDM4E | |
| SCHEMBL4842030 | 0.81 | PTPN1 (0.40) | ALDH1A1MAPTMAPK1SLC6A4SLC6A3 | |
| SCHEMBL4843947 | 0.81 | MAPK1 (0.40) | ALDH1A1HPGDMAPTTP53KDM4E | |
| SCHEMBL4840445 | 0.76 | MAPT (0.44) | ALDH1A1HPGDMAPTKDM4EMAPK1 | |
| SCHEMBL4044717 | 0.71 | NOTUM (0.56) | ALDH1A1HPGDMAPTKDM4EMAPK1 | |
| SCHEMBL8170350 | 0.70 | MAPK1 (0.48) | ALDH1A1MAPTTP53KDM4ENPSR1 | |
| Methyl Benzoate SCHEMBL27646303 | 0.70 | TSHR (0.53) | ALDH1A1HPGDMAPTKDM4ESLC6A4 | |
| SCHEMBL9949074 | 0.70 | CA12 (0.54) | ALDH1A1HPGDMAPTTP53KDM4E | |
| SCHEMBL962986 | 0.70 | MAPT (0.50) | ALDH1A1HPGDMAPTTP53KDM4E | |
| SCHEMBL5251613 | 0.70 | MAPK1 (0.38) | ALDH1A1MAPTTP53MAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7435834-B2 | 2-thia-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof | GLAXOSMITHKLINE ISTRAZIVACKI CENTER ZAGREB D.O.O. (HR) | 2008-10-14 | — | — | US | claimed |
| EP-1684702-B1 | USE OF 2-THIA-DIBENZO[E,H]AZULENES FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | GLAXOSMITHKLINE ZAGREB (HR) | 2007-09-19 | — | — | EP | claimed |
| US-20060241099-A1 | USE OF 2-THIA-DIBENZO[E,H]AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2006-10-26 | — | — | US | claimed |
| EP-1684702-A2 | USE OF 2-THIA-DIBENZO(E,H) AZULENES FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEAES AND DISORDERS | PLIVA-ISTRAZIVACKI INSTITUT d.o.o. (HR) | 2006-08-02 | — | — | EP | claimed |
| EP-1509530-B1 | 2-THIA-DIBENZOAZULENES AS INHIBITORS OF TUMOUR NECROSIS FACTOR PRODUCTION AND INTERMEDIATES FOR THE PREPARATION THEREOF | PLIVA ISTRAZIVACKI INST D O O (HR) | 2006-03-15 | — | — | EP | claimed |
| US-20050182126-A1 | 2-Thia-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof | PILVA-ISTRAZIVACKI INSTITUT D.O.O. | 2005-08-18 | — | — | US | claimed |
| US-20050131056-A1 | 2- thia-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2005-06-16 | — | — | US | claimed |
| WO-2005041856-A2 | USE OF 2-THIA-DIBENZO[E, H]AZULENES FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2005-05-12 | — | — | WO | claimed |
| US-7435834-B2 | 2-thia-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof | GLAXOSMITHKLINE ISTRAZIVACKI CENTER ZAGREB D.O.O. (HR) | 2008-10-14 | — | — | US | disclosed |
| EP-1684702-B1 | USE OF 2-THIA-DIBENZO[E,H]AZULENES FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | GLAXOSMITHKLINE ZAGREB (HR) | 2007-09-19 | — | — | EP | disclosed |
| US-20060241099-A1 | USE OF 2-THIA-DIBENZO[E,H]AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2006-10-26 | — | — | US | disclosed |
| EP-1509530-B1 | 2-THIA-DIBENZOAZULENES AS INHIBITORS OF TUMOUR NECROSIS FACTOR PRODUCTION AND INTERMEDIATES FOR THE PREPARATION THEREOF | PLIVA ISTRAZIVACKI INST D O O (HR) | 2006-03-15 | — | — | EP | disclosed |
| US-20050182126-A1 | 2-Thia-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof | PILVA-ISTRAZIVACKI INSTITUT D.O.O. | 2005-08-18 | — | — | US | disclosed |
| US-20050131056-A1 | 2- thia-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2005-06-16 | — | — | US | disclosed |
| EP-1509530-A1 | 2-THIA-DIBENZOAZULENES AS INHIBITORS OF TUMOUR NECROSIS FACTOR PRODUCTION AND INTERMEDIATES FOR THE PREPARATION THEREOF | PLIVA-ISTRAZIVACKI INSTITUT d.o.o. (HR) | 2005-03-02 | — | — | EP | disclosed |
| WO-2003084962-A1 | 2-THIA-DIBENZOAZULENES AS INHIBITORS OF TUMOUR NECROSIS FACTOR PRODUCTION AND INTERMEDIATES FOR THE PREPARATION THEREOF | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2003-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182126-A1 | 2-Thia-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof | IL1A, TNF, IL1B | ALDH1A1 45/4885HPGD 113/4885MAPT 1499/4885 |
| US-20060241099-A1 | USE OF 2-THIA-DIBENZO[E,H]AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | DBH, MAOB, BCHE | ALDH1A1 208/4885HPGD 190/4885MAPT 299/4885 |
| US-20050131056-A1 | 2- thia-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof | IL1A, TNF, IL1B | ALDH1A1 45/4885HPGD 118/4885MAPT 1572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.